TY - JOUR AU - Linke, Christian AU - Wösle, Markus AU - Harder, Anja PY - 2020 DA - 2020/09/18 TI - Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model JO - BMC Cancer SP - 896 VL - 20 IS - 1 AB - Anticancer compound 3-bromopyruvate (3-BrPA) suppresses cancer cell growth via targeting glycolytic and mitochondrial metabolism. The malignant peripheral nerve sheath tumor (MPNST), a very aggressive, therapy resistant, and Neurofibromatosis type 1 associated neoplasia, shows a high metabolic activity and affected patients may therefore benefit from 3-BrPA treatment. To elucidate the specific mode of action, we used a controlled cell model overexpressing proteasome activator (PA) 28, subsequently leading to p53 inactivation and oncogenic transformation and therefore reproducing an important pathway in MPNST and overall tumor pathogenesis. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-020-07397-w DO - 10.1186/s12885-020-07397-w ID - Linke2020 ER -